A 44 Year Old Man with Chronic Myeloid Leukemia and Mass at Right Lower Leg
DOI:
https://doi.org/10.21776/ub.jkb.2017.029.04.17Keywords:
Chronic myeloid leukemia, CML, hydroxyurea, mass legAbstract
Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder of primitive hematopoetic stem cells that is characterized by overproduction of myeloid series cells, splenomegaly, and leukocytosis. We reported a case of 44 years old male with CML who complained about swelling right leg and pain for 3 month. It had been diagnosed as CML for 3 years, and he took hydroxyurea but stopped for a year due to economic problem. The results of clinical examination, laboratory, biopsy, and radiology showed a result matched to CML with soft tissue mass. The results of Fine Needle Aspiration Biopsy (FNAB) of fragmented histiocytes leg mass, multinucleated giant cells, and atypical nucleated with a possibility of fibroma with atypical nucleated cells. Magnetic resonance imaging (MRI) showed multilocular lobulated soft tissue mass from the popliteal region to the cruris dextra, cyst mass high protein dd/solid tumor with vascular encasement and lesions in bone marrow replacement, and fluid collection on bursa parapatella. The patient was treated with hydroxyurea and showed clinical improvement and decreased mass size in the legs.
Downloads
References
American Cancer Society. Leukimia-Chronic Myeloid (Myelogenous). Atlanta: American Cancer Society; 2015; pp. 1-24.
Kantarjian H and O'Brien S. The Chronic Leukemias-Chronic Myelogenous Leukimia. In: Goldman L and Schafer AI (Ed). Goldman's Cecil Medicine 24th edition. Philadelphia: Elsevier; 2012: pp. 1209-1214.
Kanellopoulou T, Kontopidou FN, Skondra M, Pliarchopoulau K, and Pectasides D. Chronic Myelogenous Leukemia and Colon Cancer: A Causal Relationship or Coincidence? Annals of Gastroenterology. 2011; 24(2): 140-141.
Vakili-Sadeghi M and Omranpour M. Chronic Myeloid Leukemia Following Colon Cancer Treatment: A Case Report and Literature Review. Caspian Journal Internal Medicine. 2013; 4(3): 739-742.REFERENCES
American Cancer Society. Leukimia-Chronic Myeloid (Myelogenous). Atlanta: American Cancer Society; 2015; pp. 1-24.
Kantarjian H and O'Brien S. The Chronic Leukemias-Chronic Myelogenous Leukimia. In: Goldman L and Schafer AI (Ed). Goldman's Cecil Medicine 24th edition. Philadelphia: Elsevier; 2012: pp. 1209-1214.
Kanellopoulou T, Kontopidou FN, Skondra M, Pliarchopoulau K, and Pectasides D. Chronic Myelogenous Leukemia and Colon Cancer: A Causal Relationship or Coincidence? Annals of Gastroenterology. 2011; 24(2): 140-141.
Vakili-Sadeghi M and Omranpour M. Chronic Myeloid Leukemia Following Colon Cancer Treatment: A Case Report and Literature Review. Caspian Journal Internal Medicine. 2013; 4(3): 739-742.
Melo JV and Barnes DJ. Chronic Myeloid Leukaemia as a Model of Disease Evolution in Human Cancer. Nature Reviews Cancer. 2007; 7(6): 441-453.
Cui Y, Liu T, Zhou Y, et al. Five Cases Report of Solid Tumor Synchronously with Hematologic Malignancy. Cancer Research and Treatment. 2012; 44(1): 63-68.
da Silva-Santos PS, Silva BS, Coracin FL, Yamamoto FP, Pinto-Junior DD, Magalhães MG. Granulocytic Sarcoma of the Oral Cavity in a Chronic Myeloid Leukemia Patient: An Unusual Presentation. Medicina Oral Patologia Oral y Cirugia Bucal. 2010; 15(2): e350-e352.
Horne SD, Stevens JB, Abdallah BY, et al. Why Imatinib Remains an Exception of Cancer Research. Journal of Cellular Physiology. 2013; 228(4): 665-670.
Jabbour E and Kantarjian H. Chronic Myeloid Leukemia: 2014 Update on Diagnosis, Monitoring, and Management. American Journal of Hematology. 2014; 89(5): 548-556.
Cohen M, Williams G, Johnson R, Duan J, Gobburu J, Rahman A, et al. Apprroval Summary for Imatinib Mesylate Capsules in the Treatment of Chronic Myelogenous Leukemia. Clinical Cancer Research. 2002; 8(5): 935-942.
Westin JR and Kurzrock R. It's About Time: Lessons for Solid Tumors from Chronic Myelogenous Leukemia Therapy. Molecular Cancer Therapeutics. 2012; 11(12): 2549-2555.
Jenkins CI and Sorour Y. Case Report : A Large Extramedullary Granulocytic Sarcoma as the Initial Presenting Feature of Chronic Myeloid Leukemia. Medscape General Medicine. 2005; 7 (4): 23.
Druker B, Guilhot F, O'Brien S, et al. Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukimia. The New England Journal medicine. 2006; 355(12): 2408-2417.
Melo JV and Barnes DJ. Chronic Myeloid Leukaemia as a Model of Disease Evolution in Human Cancer. Nature Reviews Cancer. 2007; 7(6): 441-453.
Cui Y, Liu T, Zhou Y, et al. Five Cases Report of Solid Tumor Synchronously with Hematologic Malignancy. Cancer Research and Treatment. 2012; 44(1): 63-68.
da Silva-Santos PS, Silva BS, Coracin FL, Yamamoto FP, Pinto-Junior DD, Magalhães MG. Granulocytic Sarcoma of the Oral Cavity in a Chronic Myeloid Leukemia Patient: An Unusual Presentation. Medicina Oral Patologia Oral y Cirugia Bucal. 2010; 15(2): e350-e352.
Horne SD, Stevens JB, Abdallah BY, et al. Why Imatinib Remains an Exception of Cancer Research. Journal of Cellular Physiology. 2013; 228(4): 665-670.
Jabbour E and Kantarjian H. Chronic Myeloid Leukemia: 2014 Update on Diagnosis, Monitoring, and Management. American Journal of Hematology. 2014; 89(5): 548-556.
Cohen M, Williams G, Johnson R, Duan J, Gobburu J, Rahman A, et al. Apprroval Summary for Imatinib Mesylate Capsules in the Treatment of Chronic Myelogenous Leukemia. Clinical Cancer Research. 2002; 8(5): 935-942.
Westin JR and Kurzrock R. It's About Time: Lessons for Solid Tumors from Chronic Myelogenous Leukemia Therapy. Molecular Cancer Therapeutics. 2012; 11(12): 2549-2555.
Jenkins CI and Sorour Y. Case Report : A Large Extramedullary Granulocytic Sarcoma as the Initial Presenting Feature of Chronic Myeloid Leukemia. Medscape General Medicine. 2005; 7 (4): 23.
Druker B, Guilhot F, O'Brien S, et al. Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukimia. The New England Journal medicine. 2006; 355(12): 2408-2417.
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
